Literature DB >> 1138553

Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man.

J A Robinson, M L Klondnycky, H S Loeb, M R Racic, R M Gunnar.   

Abstract

Eighteen patients were studied prior to and again within 6 hours after transurethral resection or cystoscopy. In addition to hemodynamic measurements, detection of endotoxin by limulus assay and bacteriologic sampling; prekallikrein, C3, C3 proactivator and lysosomal enzyme levels were measured. In five patients limulus assays were positive, and in one, gram-positive bacteremia developed but limulus assay remained negative. All six had significant decreases in prekallikrein, C3 or C3 proactivator. Systemic vascular resistance fell in all six. Four additional patients who had a decrease in systemic vascular resistance were not endotoxemic or bacteremic; one of these had a decrease in prekallikrein only. In the remaining eight patients with neither bacteremia nor endotoxemia, systemic vascular resistance did not change or increase after instrumentation. One had a decrease in C3 proactivator, another in prekallikrein. There was no significant difference in age, disease, antibiotic therapy or bactermia in the two groups of patients. Four of the five resectional procedures were performed in the group that showed decreases in systemic vascular resistance. The data suggest that acute endotoxemia or gram-positive bacteremia in man is associated with depletion of prekallikrein, decreased peripheral resistance and, in some instances, activation of the complement system.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138553     DOI: 10.1016/0002-9343(75)90322-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Effect of hydration status on cerebral blood flow and cerebrospinal fluid lactic acidosis in rabbits with experimental meningitis.

Authors:  J H Tureen; M G Täuber; M A Sande
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

2.  Peripheral vascular resistance in septic shock: its relation to outcome.

Authors:  A B Groeneveld; J J Nauta; L G Thijs
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

Review 3.  The effects of bacterial endotoxins on host mediation systems. A review.

Authors:  D C Morrison; R J Ulevitch
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

Review 4.  Immunological aspects to severe bacterial sepsis.

Authors:  N Clumeck; C George
Journal:  Intensive Care Med       Date:  1981-04       Impact factor: 17.440

5.  [Hepato-renal syndrome (author's transl)].

Authors:  J Kipnowski; R Düsing; H J Kramer
Journal:  Klin Wochenschr       Date:  1981-05-04

6.  Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.

Authors:  C Cordova; F Violi; C Alessandri; D Ferro; M Saliola; F Balsano
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

7.  Activation of the contact system in lethal hypotensive bacteremia in a baboon model.

Authors:  R A Pixley; R A DeLa Cadena; J D Page; N Kaufman; E G Wyshock; R W Colman; A Chang; F B Taylor
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

Review 8.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

9.  Circulating immune complexes in patients with gram negative septic shock.

Authors:  C George; J Carlet; A Sobel; L Intrator; M Robin; C Sabatier; D Prevot; M Rapin
Journal:  Intensive Care Med       Date:  1980       Impact factor: 17.440

10.  Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats.

Authors:  M Katori; M Majima; R Odoi-Adome; N Sunahara; Y Uchida
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.